Silk Road Medical Stock Price, News & Analysis

Silk Road Medical (NASDAQ: SILK) announced plans to release its financial results for Q4 and the full year 2022 on February 28, 2023, after market close. Following this, management will host an audio webcast at 1:30 PM PT / 4:30 PM ET. The company specializes in reducing stroke risks through its innovative TransCarotid Artery Revascularization (TCAR) procedure, which combines surgical neuroprotection principles with minimally invasive techniques. Interested participants can register online for the conference call. For further details, visit Silk Road Medical's investor relations page.

Silk Road Medical, Inc. (NASDAQ: SILK) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. Management will present on January 10, 2023, at 4:30 p.m. PT. Interested parties can access a live and archived webcast via the company's website.

Based in Sunnyvale, California, Silk Road Medical focuses on reducing stroke risks through its innovative TransCarotid Artery Revascularization (TCAR) procedure, which treats carotid artery blockages with a minimally invasive approach.

Silk Road Medical (SILK) reported a 51% increase in Q3 2022 revenue, totaling $37.4 million, driven by growing adoption of TCAR. Gross profit reached $28.1 million with a consistent gross margin of 75%. Operating expenses rose to $37.3 million, reflecting increased personnel and investments in R&D. The net loss narrowed to $10.3 million or $0.29 per share, compared to a greater loss last year. The company expects full-year revenue between $134 million and $137 million, signifying 32% to 35% growth year-over-year.

Silk Road Medical (Nasdaq: SILK) announced its participation in upcoming investor conferences. The presentations will occur at:

• Stifel 2022 Healthcare Conference on November 15 at 10:20 a.m. Eastern Time
• 4th Annual Wolfe Research Healthcare Conference on November 16 at 1:20 p.m. Eastern Time
• 34th Annual Piper Sandler Healthcare Conference on November 30 at 3:00 p.m. Eastern Time

Webcasts of the presentations will be available in the “Investors” section of their website.

Silk Road Medical (Nasdaq: SILK) announced it will report its third quarter 2022 financial results on November 8th, 2022, after market close. A live audio webcast will follow, starting at 1:30 p.m. PT / 4:30 p.m. ET. Interested participants can register here. Silk Road Medical, based in Sunnyvale, focuses on reducing stroke risks through its TransCarotid Artery Revascularization (TCAR) procedure.

Silk Road Medical (NASDAQ: SILK) has announced a public offering of 2,325,582 shares at $43.00 each, intending to raise approximately $100 million. The underwriters have a 30-day option to purchase an additional 348,837 shares. Proceeds will support expansion of sales and operations, R&D, clinical studies, and potential facility leasing. While potential debt repayment and acquisitions are mentioned, no current agreements exist. Closing is expected on October 21, 2022, pending customary conditions.

Silk Road Medical (Nasdaq: SILK) announced preliminary financial data for Q3 2022, reporting an estimated revenue of $37.4 million, a 51% increase from $24.7 million in Q3 2021. Gross profit is estimated between $27.8 million and $28.2 million, resulting in a gross margin of 74% to 75%. Operating expenses rose to an estimated $37.2 million to $37.6 million, up 17-18% from the previous year. The estimated net loss decreased to between $10.2 million and $10.6 million, down from $13.9 million in Q3 2021. Cash reserves stand at $105.1 million.

Silk Road Medical (NASDAQ: SILK) has announced a proposed underwritten public offering of $100 million of its common stock, with an option for underwriters to purchase an additional 15% of shares sold. The offering's completion is subject to market conditions. Proceeds will be allocated to expand operations, increase R&D, and support clinical trials, with potential debt repayment and acquisitions. The offering is registered under Form S-3 with the SEC. J.P. Morgan and BofA Securities are the lead managers for this transaction.

Silk Road Medical (NASDAQ: SILK) has successfully enrolled the first patient in its ROADSTER 3 study, designed to evaluate TCAR treatment for patients with carotid artery disease at standard surgical risk. The study will include up to 400 patients across 60 sites, assessing major adverse events and other secondary endpoints. This milestone meets FDA post-approval study requirements and aims to confirm TCAR's safety and efficacy in real-world settings. The procedure, led by Dr. Animesh Rathore, marks a significant step in validating this less invasive treatment option.